Nevertheless, besides its potential effects in inducing adiponectin expression, PPAR-γ agonists especially presented several side effects, such as weight gain, cardiac failure or edema, suggesting an imbalance between clinical benefits of elevated adiponectin concentrations and expected unfavourable metabolic side effects [102]. The gene discussed is ADIPOQ; the disease is heart failure.